Dartmouth Hitchcock Medical Center, which is part of the Dartmouth Health system, is the U.S. state of New Hampshire's only academic medical center. DHMC is a 396-inpatient bed hospital and serves as a major tertiary-care referral site for patients throughout northern New England.

There are 396 beds in Dartmouth-Hitchcock Comprehensive Hemophilia and Thrombosis Center.

During the past decade, Dartmouth-Hitchcock Comprehensive Hemophilia and Thrombosis Center conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dartmouth-Hitchcock Comprehensive Hemophilia and Thrombosis Center" #1 collaborator was "American Thrombosis and Hemostasis Network" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Bioverativ Therapeutics Inc." with 1 trials as a collaborator, "CSL Behring" with 1 trials as a collaborator and "Shire" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Dartmouth-Hitchcock Comprehensive Hemophilia and Thrombosis Center" are "Hemophilia" (1 trials) and "Hemophilia A" (1 trials). Many other conditions were trialed in "Dartmouth-Hitchcock Comprehensive Hemophilia and Thrombosis Center" in a lesser frequency.

Most popular intervention types in "Dartmouth-Hitchcock Comprehensive Hemophilia and Thrombosis Center" are "Biological" (1 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013" (1 trials), "Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013" (1 trials) and "New FVIII products" (1 trials). Other intervention names were less common.

The vast majority of trials in "Dartmouth-Hitchcock Comprehensive Hemophilia and Thrombosis Center" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Dartmouth-Hitchcock Comprehensive Hemophilia and Thrombosis Center". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Dartmouth-Hitchcock Comprehensive Hemophilia and Thrombosis Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Dartmouth-Hitchcock Comprehensive Hemophilia and Thrombosis Center, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".